within Pharmacolibrary.Drugs.ATC.A;

model A16AB22
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.28833333333333333,
    adminDuration  = 600,
    adminMass      = 2.0,
    adminCount     = 1,
    Vd             = 0.056100000000000004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Avalglucosidase alfa is a recombinant human acid alpha-glucosidase enzyme indicated for long-term enzyme replacement therapy in patients with Pompe disease (acid alpha-glucosidase deficiency). It is approved for use in the treatment of late-onset Pompe disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult subjects with late-onset Pompe disease after intravenous administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A16AB22;
